[1]王跃慧,李春彦.匹伐他汀与阿托伐他汀对缺血性卒中患者疗效及安全性的对比研究[J].医学信息,2022,35(08):150-152.[doi:10.3969/j.issn.1006-1959.2022.08.038]
　WANG Yue-hui,LI Chun-yan.A comparative Study of the Efficacy and Safety of Pivastatin and Atorvastatin in Patients with Ischemic Stroke[J].Medical Information,2022,35(08):150-152.[doi:10.3969/j.issn.1006-1959.2022.08.038]
点击复制

匹伐他汀与阿托伐他汀对缺血性卒中患者疗效及安全性的对比研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年08期
页码:
150-152
栏目:
药物与临床
出版日期:
2022-04-15

文章信息/Info

Title:
A comparative Study of the Efficacy and Safety of Pivastatin and Atorvastatin in Patients with Ischemic Stroke
文章编号:
1006-1959（2022）08-0150-03
作者:
王跃慧; 李春彦
（天津市蓟州区人民医院综合内科，天津 301900）
Author(s):
WANG Yue-hui; LI Chun-yan
(1.Department of Neurology,Binhai Hospital,General Hospital of Tianjin Medical University,Tianjin 300480,China;2.Department of Cardiology,the Second Affiliated Hospital of Hebei North University,Zhangjiakou 075100,Hebei,China)
关键词:
甲亢; 甲巯咪唑; 丙硫氧嘧啶; 甲状腺功能; 肝功能
Keywords:
Pitavastatin; Atorvastatin; Ischemic stroke; Blood lipid; NIHSS score
分类号:
R581.1
DOI:
10.3969/j.issn.1006-1959.2022.08.038
文献标志码:
A
摘要:
目的 分析甲巯咪唑与丙硫氧嘧啶对甲亢患者甲状腺功能及肝功能指标的影响，为临床用药提供参考。方法 选取2020年3月-2021年3月收治的84例甲亢患者，按照随机数字表法分为甲巯咪唑组与丙硫氧嘧啶组，各42例，分别给予甲巯咪唑与丙硫氧嘧啶口服治疗。比较两组甲状腺功能指标[促甲状腺激素（TSH）、三碘甲腺原氨酸（FT3）、四碘甲腺原氨酸（FT4）]、肝功能指标[丙氨酸氨基转移酶（ALT）、天冬氨酸氨基转移酶（AST）、谷氨酰转肽酶（GGT）]、肝功能受损情况及不良反应。结果 两组FT3、FT4低于治疗前，TSH高于治疗前，且甲巯咪唑组FT3、FT4低于丙硫氧嘧啶组，TSH高于丙硫氧嘧啶组，差异有统计学意义（P＜0.05）；丙硫氧嘧啶组ALT、AST、GGT高于治疗前，且高于甲巯咪唑组，差异有统计学意义（P＜0.05）；甲巯咪唑组治疗前后ALT、AST、GGT比较，差异无统计学意义（P＞0.05）；甲巯咪唑组肝损伤率为4.76%，低于丙硫氧嘧啶组的19.05%，差异有统计学意义（P＜0.05）；两组不良反应总发生率比较，差异无统计学意义（P＞0.05）。结论 甲巯咪唑与丙硫氧嘧啶均可有效改善甲亢患者的甲状腺功能，前者效果更佳，且肝损伤毒性更小。
Abstract:
Objective To compare the efficacy and safety of pitavastatin and atorvastatin in the treatment of ischemic stroke.Methods A total of 100 patients with ischemic stroke admitted to Binhai Hospital,General Hospital of Tianjin Medical University from October 2017 to September 2018 were selected as the study subjects. They were divided into control group and observation group by random number table method, with 50 cases in each group. The control group was treated with atorvastatin, and the observation group was treated with pitavastatin. The total effective rate, blood lipid index, NIHSS score, serum creatinine, urea nitrogen, white blood cell count, platelet count and urine protein positive rate were compared between the two groups.Results The total effective rate of the observation group was 86.00%, which was higher than 82.00% of the control group, and the difference was not statistically significant (P>0.05). The levels of LDL-C, TG and TC of the two groups were lower than those before treatment, and those in the observation group was lower than the control group, the difference was statistically significant (P<0.05). NIHSS scores of the two groups were lower than those before treatment, and the difference was statistically significant (P<0.05), however, there was no significant difference between groups (P>0.05). The positive rates of serum creatinine, urea nitrogen, white blood cell count and urinary protein in the observation group were lower than those in the control group, and the platelet count was higher than that in the control group, the difference was statistically significant (P<0.05).Conclusion The efficacy of pitavastatin and atorvastatin in the treatment of ischemic stroke is similar, but pitavastatin reduces blood lipid levels more significantly, and can alleviate adverse drug reactions to a certain extent, which has certain clinical application advantages.

参考文献/References:

[1]郭刚.阿托伐他汀联合阿司匹林对急性缺血性脑卒中患者血脂及神经功能缺损程度的影响[J].中国医药导报,2015,12(28):108-111.[2]王红,龚平.阿托伐他汀联合拜阿司匹林对糖尿病患者炎症因子、血管内皮功能及心血管事件的影响[J].海南医学院学报,2016,22(5):441-443.[3]杨姗姗,王建华,何耀,等.老年人群缺血性脑卒中与血脂异常的关系[J].中华老年心脑血管病杂志,2017,19(9):901-905.[4]孔辉.阿托伐他汀对老年缺血性脑卒中患者氧化应激及脂质过氧化的影响[J].中国实用神经疾病杂志,2018,21(14):1605-1608.[5]中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志,2018,51(9):666-682.[6]蔡敬杰,张素芳,逄涛.阿托伐他汀治疗急性缺血性脑卒中患者颈动脉粥样硬化斑块的效果观察[J].国际医药卫生导报,2016,22(23):3620-3622.[7]张羚.阿托伐他汀治疗急性缺血性脑卒中患者颈动脉粥样硬化斑块临床研究[J].中国实用神经疾病杂志,2016(3):73-74.[8]刘绪龙.阿托伐他汀强化调脂对缺血性脑卒中患者的影响[J].神经损伤与功能重建,2016,11(3):248-250.[9]陈德艳,周慧,陈赟,等.强化阿托伐他汀治疗缺血性脑卒中的疗效及其对患者血清血管性假血友病因子和血管内皮细胞钙黏蛋白水平的影响[J].海南医学,2019,30(2):163-165.[10]Li M,Wu J,Chen X,et al.Symptomatic and silent cerebral infarction following surgical clipping of unruptured intracranial aneurysms:incidence,risk factors,and clinical outcome[J].Neurosurgical Review,2018,41(2):675-682.[11]孟明,张春梅,赵旭伟,等.阿司匹林联合阿托伐他汀对脑卒中大鼠脑组织神经生长相关蛋白43与血管内皮生长因子表达的影响及治疗老年急性缺血性脑卒中的疗效[J].中国老年学,2015(10):2641-2644.[12]权素芳.高强度阿托伐他汀联合氯吡格雷对缺血性脑卒中患者卒中相关蛋白水平及预后的影响[J].中国药物与临床,2019,19(8):1278-1281.[13]路延丽,乔向东,叶芳.通心络胶囊联合阿司匹林和阿托伐他汀对缺血性脑卒中二级预防的疗效分析[J].贵州医药,2018,42(3):318-320.[14]朱敏,石琳,王雯,等.匹伐他汀与阿托伐他汀对冠心病并非酒精性脂肪性肝病患者血脂代谢和肝功能影响的对比研究[J].实用心脑肺血管病杂志,2018,26(4):71-73.[15]刘思宁,栾天竹.匹伐他汀、阿托伐他汀及瑞舒伐他汀对非糖尿病冠心病患者血糖代谢影响[J].临床军医杂志,2016,44(5):520-523.[16]彭莹娟,赵倩,杨会杰.缺血性脑卒中患者采用匹伐他汀与阿托伐他汀治疗对于血脂调控的临床比较[J].现代诊断与治疗,2020,31(10):1579-1580.[17]袁远,徐燕,高旭光.匹伐他汀与阿托伐他汀对缺血性卒中患者疗效及安全性的对比研究[J].中华脑血管病杂志(电子版),2015,8(1):1-8.

相似文献/References:

[1]苗艳茹.甲巯咪唑与糖皮质激素联合治疗甲状腺功能亢进症合并症的效果分析[J].医学信息,2018,31(05):136.[doi:10.3969/j.issn.1006-1959.2018.05.048]
　MIAO Yan-ru.Analysis of Effects of Methimazole and Glucocorticoids on Complications of Hyperthyroidism[J].Medical Information,2018,31(08):136.[doi:10.3969/j.issn.1006-1959.2018.05.048]
[2]康 凯,郑继伟,王 闰.糖皮质激素治疗甲亢伴浸润性突眼的疗效分析[J].医学信息,2018,31(08):103.[doi:10.3969/j.issn.1006-1959.2018.08.033]
　KANG Kai,ZHENG Ji-wei,WANG Run.Efficacy of Glucocorticoids in the Treatment of Hyperthyroidism with Infiltrating Exophthalmos[J].Medical Information,2018,31(08):103.[doi:10.3969/j.issn.1006-1959.2018.08.033]
[3]孙清林.放射性核素131I在甲亢治疗中的安全性与有效性分析[J].医学信息,2018,31(15):120.[doi:10.3969/j.issn.1006-1959.2018.15.038]
　SUN Qing-lin.Safety and Efficacy Analysis of Radionuclide 131I in the Treatment of Hyperthyroidism[J].Medical Information,2018,31(08):120.[doi:10.3969/j.issn.1006-1959.2018.15.038]
[4]蒋红梅.丙基硫氧嘧啶与甲巯咪唑治疗妊娠合并甲状腺功能亢进的疗效比较[J].医学信息,2019,32(05):154.[doi:10.3969/j.issn.1006-1959.2019.05.049]
　JIANG Hong-mei.Comparison of Propyl Thiouracil and Methimazole in the Treatment of Pregnancy with Hyperthyroidism[J].Medical Information,2019,32(08):154.[doi:10.3969/j.issn.1006-1959.2019.05.049]
[5]丹杨萍,谭丽艳,刘思聪,等.甲巯咪唑对Graves病患者血清FCRL3水平的影响[J].医学信息,2020,33(07):149.[doi:10.3969/j.issn.1006-1959.2020.07.048]
　DAN Yang-ping,TAN Li-yan,LIU Si-cong,et al.Effect of Methimazole on Serum FCRL3 Level in Patients with Graves Disease[J].Medical Information,2020,33(08):149.[doi:10.3969/j.issn.1006-1959.2020.07.048]
[6]姜丽莉,王 静,李振凤,等.甲巯咪唑对初诊Graves’病患者血清相关细胞因子及microRNAs水平的影响[J].医学信息,2020,33(08):101.[doi:10.3969/j.issn.1006-1959.2020.08.031]
　JIANG Li-li,WANG Jing,LI Zhen-feng,et al.Effects of Methimazole on Serum Levels of Cytokines and microRNAs in Newly Diagnosed Graves’ Disease Patients[J].Medical Information,2020,33(08):101.[doi:10.3969/j.issn.1006-1959.2020.08.031]
[7]张 晶.FT3、FT4、TSH与T3、T4联检评价甲状腺功能的临床意义[J].医学信息,2020,33(12):164.[doi:10.3969/j.issn.1006-1959.2020.11.054]
　ZHANG Jing.Clinical Significance of FT3,FT4,TSH and T3,T4 Joint Evaluation of Thyroid Function[J].Medical Information,2020,33(08):164.[doi:10.3969/j.issn.1006-1959.2020.11.054]
[8]魏月茹,康学东.康学东教授运用丹栀逍遥散合酸枣仁汤治疗肝郁阴虚型甲亢失眠临床经验[J].医学信息,2021,34(07):160.[doi:10.3969/j.issn.1006-1959.2021.07.045]
[9]徐晨曦.甲巯咪唑与丙硫氧嘧啶对甲亢患者甲状腺功能及肝功能指标的影响[J].医学信息,2022,35(08):147.[doi:10.3969/j.issn.1006-1959.2022.08.037]
　XU Chen-xi.Effect of Methimazole and Propylthiouracil on Thyroid Function and Liver Function in Patients with Hyperthyroidism[J].Medical Information,2022,35(08):147.[doi:10.3969/j.issn.1006-1959.2022.08.037]

更新日期/Last Update: 1900-01-01